Ascentage Pharma Group International (NASDAQ:AAPG) Trading Down 4.9% - Time to Sell?

Key Points

• AAPG shares fell 4.9% to $17.15 in thin trading, with volume down 96% from the average session level.
• Despite the decline, analysts remain bullish: the stock has an average “Buy” rating and a consensus price target of $46.43, substantially above its current price.
• Ascentage reported a quarterly loss of $0.65 per share on $22.24 million in revenue, while institutional investors including UBS, HSBC, and Citadel recently established or increased positions.

Shares of Ascentage Pharma Group International - Unsponsored ADR (NASDAQ:AAPG - Get Free Report) were down 4.9% during trading on Friday . The stock traded as low as $17.15 and last traded at $17.15. 307 shares were traded during mid-day trading, a decline of 96% from the average session volume of 6,895 shares. The stock had previously closed at $18.03.

Wall Street Analyst Weigh In

Several analysts recently weighed in on AAPG shares. B. Riley Financial started coverage on shares of Ascentage Pharma Group International in a report on Wednesday, June 10th. They issued a "buy" rating and a $45.00 target price on the stock. Deutsche Bank Aktiengesellschaft began coverage on shares of Ascentage Pharma Group International in a research report on Friday, April 24th. They set a "buy" rating and a $40.00 price objective for the company. Raymond James Financial reiterated a "buy" rating on shares of Ascentage Pharma Group International in a research report on Wednesday, June 10th. Finally, BTIG Research reiterated a "buy" rating and set a $48.00 price target on shares of Ascentage Pharma Group International in a research report on Friday. Two investment analysts have rated the stock with a Strong Buy rating and eight have given a Buy rating to the stock. According to MarketBeat, Ascentage Pharma Group International currently has an average rating of "Buy" and a consensus target price of $46.43.

Ascentage Pharma Group International Trading Up 0.7%

The company has a 50-day moving average of $18.21 and a two-hundred day moving average of $21.23. The company has a debt-to-equity ratio of 0.57, a quick ratio of 1.77 and a current ratio of 1.79.

Ascentage Pharma Group International (NASDAQ:AAPG - Get Free Report) last issued its quarterly earnings results on Wednesday, August 19th. The company reported ($0.65) EPS for the quarter. The company had revenue of $22.24 million for the quarter. On average, equities analysts anticipate that Ascentage Pharma Group International - Unsponsored ADR will post -1.78 EPS for the current year.

Institutional Trading of Ascentage Pharma Group International

A number of institutional investors have recently added to or reduced their stakes in AAPG. Citadel Advisors LLC purchased a new stake in shares of Ascentage Pharma Group International during the third quarter valued at approximately $383,000. Hsbc Holdings PLC bought a new position in shares of Ascentage Pharma Group International in the 2nd quarter worth about $391,000. Finally, UBS Group AG boosted its stake in Ascentage Pharma Group International by 149.4% in the third quarter. UBS Group AG now owns 18,345 shares of the company's stock valued at $716,000 after acquiring an additional 10,988 shares during the period.

Ascentage Pharma Group International Company Profile

Ascentage Pharma Group International is a clinical‐stage biopharmaceutical company focused on developing small‐molecule therapeutics that modulate programmed cell death pathways, including the Bcl‐2 family and the MDM2–p53 axis. Its pipeline features orally bioavailable inhibitors such as APG-2575, a selective Bcl-2 inhibitor, and APG-115, a potent MDM2 antagonist, both aimed at reactivating apoptosis in cancer cells across hematologic malignancies and solid tumors.

Founded in 2008 by biotechnology entrepreneur Dr.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source